Clarithromycin Taste Masked Granules 27.5%, 30%, 33%, 42%, 43.75% – Suitable for Capsules, Tablets, Suspensions (DOSE: 125 mg, 250 mg, 500 mg)

Clarithromycin is used to treat a wide variety of bacterial infections including the one’s caused by H. PYLORI. This medication can also be used in combination with anti-ulcer medications to treat certain types of stomach ulcers. It may also be used to prevent certain bacterial infections.

  • Murli Krishna Pharma Pvt. Ltd. is a leading global PFI manufacturer and supplier for Clarithromycin PFI as granules.
  • The process of Manufacturing Clarithromycin Taste Masked Pellets of MKPPL is completely aqueous based. No solvent has been used in any stage of manufacturing process. This process effectively masks the taste of the drug without compromising the dissolution rate.
  • We offer development services if different formulation/dosage/strength are required.
  • Complete technical package for registrations in all regulated/semi regulated markets are available
  • Products protected by ongoing Patents are not offered by MKPPL.

Additional information

27.5%, 30%, 33%, 42% & 43.75%

Mesh Size

30#80, 30#100

Release Type


Quality Standard


Documentation Available:

DMF in CTD Format

Forms of PFI


Target Formulations

Capsules, Suspension, Tablets


Clarithromycin is a semi-synthetic macrolide antibiotic. Chemically, it is 6-0 methyl erythromycin. The molecular formula is C38H69NO13, and the molecular weight is 747.96

Clarithromycin is a white to off-white crystalline powder. It is soluble in acetone, slightly soluble in methanol, ethanol, and acetonitrile, and practically insoluble in water.

Clarithromycin is a member of macrolide antibiotic. It binds to the 50S sub unit of bacterial ribosome and inhibits translocation i.e. they interfere with the transfer of the newly formed peptide chain from the A site to the P site and fails to expose the A site. So that A site is unable to bind with the next aminoacyl tRNA complex. This leads to premature termination of amino acid chain and there by inhibits protein synthesis.

The innovator is BIAXIN which is available as Immediate-release tablets, Extended-release tablets, and Granules for oral suspension. After constitution, each 5 mL of BIAXIN suspension contains 125 mg or 250 mg of clarithromycin. Each bottle of BIAXIN granules contains 1250 mg (50 mL size), 2500 mg (50 and 100 mL sizes) or 5000 mg (100 mL size) of clarithromycin and the following inactive ingredients: carbomer, castor oil, citric acid, hypromellose phthalate, maltodextrin, potassium sorbate, povidone, silicon dioxide, sucrose, xanthan gum, titanium dioxide and fruit punch flavor.

Non-infringing Process: The process of Manufacturing Clarithromycin Taste Masked Pellets of MKPPL is completely aqueous based. No solvents are been used in any stage of manufacturing process. The manufacturing process includes Drug coating on sugar micro pellets followed by taste masker coating and Methacrylic acid copolymer coating. The object of the present invention is to provide a taste masked composition, which effectively masks the taste of the drug without compromising the dissolution rate.

The key excipient: used for taste masking is Carbopol and Methacrylic acid copolymer.

Applications: Clarithromycin TM pellets are in MUPS form with particle size from 180 micron to 600 micron hence has multiple use as for Tablet Compression, Dry syrup for suspension, and Sachet.

The oral taste masked granules are capable of being administered as coated granules dry syrups, sachets and powders that can be reconstituted before usage as a liquid suspension. The reconstitutable compositions prepared from granules are stable during storage and the suspensions, once reconstituted, present a masked taste during the entire course of treatment.

The sachet formulations are solid powders containing three essential components:

  • Coated spherical micro particles
  • Partially recrystallized shear form floss particles produced from compositions containing Saccharide based carrier
  • Additives selected from the group consisting of lubricants, flavors, glidants, fillers and colorants.

When ingested, the combinations become somewhat syrupy in the mouth, giving a pleasing mouth feel and enhanced organoleptic acceptability.

Sachets of 250 mg are indicated in adults and children 12 years and older.

Bi-compartment Sachet can be designed in such a way that one compartment contains the Clarithromycin TM Pellets/Granules and another compartment contains suspension premix. The content of both the compartments to be emptied in small quantity of Water and consumed.

This technology of bi-compartment sachet increases the stability of the product in dry syrup form.

Privacy Preference Center